{"id":"W4408675158","doi":"10.1210/clinem/dgaf178","title":"Immune Checkpoint Inhibitor Therapy for Aggressive Pituitary Neuroendocrine Tumors","year":2025,"lang":"en","type":"article","venue":"The Journal of Clinical Endocrinology & Metabolism","topic":"Pituitary Gland Disorders and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; Instituto Nacional do Câncer, Ministério da Saúde; Bristol-Myers Squibb Canada; National Institutes of Health; Society of Memorial Sloan Kettering","keywords":"Medicine; Nivolumab; Oncology; Ipilimumab; Temozolomide; Internal medicine; Clinical endpoint; Pembrolizumab; Pituitary tumors; Neuroendocrine tumors; Radiation therapy; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002577716,0.0002656985,0.0004559704,0.0001120471,0.0001289154,0.0002245435,0.0001668846,0.0001498751,0.0007140532],"category_scores_gemma":[0.0002368004,0.00005656953,0.0001935266,0.0001410975,0.0001711867,0.0001619716,0.0001544427,0.0006703671,0.0001417771],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002995829,"about_ca_system_score_gemma":0.0004057971,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003137612,"about_ca_topic_score_gemma":0.001216592,"domain_scores_codex":[0.9999261,0.00001794,0.000007660818,0.00001401348,0.00002057718,0.00001365493],"domain_scores_gemma":[0.9998347,0.00003679869,0.00005722308,0.000009672893,0.00001245494,0.00004919999],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.03818025,0.002890836,0.09383071,0.003053605,0.0008115743,0.004671501,0.0003347225,0.004762297,0.2009775,0.0008649027,0.005891704,0.6437304],"study_design_scores_gemma":[0.03988929,0.2226035,0.4215629,0.0008186682,0.001901828,0.05778918,0.0006378404,0.01357786,0.1390935,0.002612176,0.09939841,0.0001147447],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9815112,0.01476525,0.0007400024,0.000469846,0.00007631079,0.0001365404,0.0001726108,0.00004094232,0.002087293],"genre_scores_gemma":[0.9946843,0.003623683,0.0007696735,0.0001885986,0.0000860705,0.00006150753,0.0002145962,0.000004463356,0.0003671114],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0007140532,"threshold_uncertainty_score":0.002388775,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03559988933634269,"score_gpt":0.373373412604133,"score_spread":0.3377735232677903,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}